Biogen Idec (Nasdaq:BIIB) hit a new 52-week high Friday as it is currently trading at $167.86, above its previous 52-week high of $167.35 with 518,977 shares traded as of 10:16 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Biogen Idec (Nasdaq: BIIB) hit a new 52-week high Friday as it is currently trading at $167.86, above its previous 52-week high of $167.35 with 518,977 shares traded as of 10:16 a.m. ET. Average volume has been 1.3 million shares over the past 30 days. Biogen Idec has a market cap of $39.21 billion and is part of the health care sector and drugs industry. Shares are up 13.3% year to date as of the close of trading on Thursday. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 28.8, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Biogen Idec Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.